Skip to main content
webosan/Dose coverage

Dose coverage

Which dose volumes your pen travel range actually covers

Most dose tables answer a question buyers do not have. You already know the approved dose of the drug you are developing. What you cannot see from outside is whether a given pen platform has the travel and the increment to deliver it — and that is what this page compares.

Why millilitres, not milligrams

A dose in mg is a property of the drug. What the pen has to do is move a volume. Two programs at the same mg can need completely different mechanisms once concentration differs, because concentration decides how many millilitres the same milligram occupies. Volume, increment and container format are the specifications that decide whether a platform fits; the milligram figure only tells you which direction to look.

This is also why we do not publish a "suitable drugs" list. A list of drug names with a tick beside it is marketing. A travel range and an increment you can check against your own fill volume is engineering.

Released travel ranges

  • 0.30 mL travel30 steps
  • 0.50 mL travel50 steps
  • 0.60 mL travel60 steps
  • 0.76 mL travel76 steps
  • 0.80 mL travel80 steps
  • 0.75 mL / 0.0208 mL step36 steps

Approved dose volume vs. platform travel

Dose volumes are taken from public prescribing information. Platform travel comes from our own released specifications. Where they do not line up, we say so.

Semaglutide

0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg

Covered
Dose volume
0.50 mL · 0.75 mL
Container
Single-dose pre-filled pen
Platform travel
0.76 mL travel

What this means in practice Dose escalation needs two container volumes, not one. The 0.25–1.0 mg strengths sit in 0.50 mL; 1.7 and 2.4 mg sit in 0.75 mL. Our 0.76 mL travel covers both, so one mechanism covers the full escalation with only the scale marking changing.

Source: EMA SmPC (semaglutide single-dose pens)

Tirzepatide

2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg

Covered
Dose volume
0.50 mL
Container
Single-dose pre-filled pen
Platform travel
0.50 mL travel

What this means in practice Six strengths, six separate pens, every one delivering a fixed 0.50 mL. The device work here is not dose dialling — it is six SKUs that must look different enough not to be confused, while the mechanism stays identical. Colour, scale print and carton logic become the engineering problem.

Source: FDA prescribing information (tirzepatide)

Liraglutide

0.6 / 1.2 / 1.8 mg daily

Covered
Dose volume
0.10 / 0.20 / 0.30 mL
Container
Multi-dose 3 mL cartridge
Platform travel
0.30 mL travel

What this means in practice One pen covers the whole schedule, so the burden moves to the low end: 0.10 mL at 6 mg/mL is a 0.6 mg dose, and the increment has to be fine enough that a 0.6 mg step is dialable without ambiguity on a printed scale.

Source: EMA SmPC / US prescribing information (liraglutide 18 mg/3 mL)

Teriparatide

20 µg daily, fixed

Needs variant
Dose volume
0.08 mL
Container
Multi-dose 2.4 mL cartridge
Platform travel
—

What this means in practice Stated honestly: 0.08 mL does not map onto a standard travel in our released range. It needs a dedicated short-travel variant with a finer increment, and that is a tooling decision taken at quotation — not something to assume. If your program is teriparatide, raise it first.

Source: US prescribing information (teriparatide 250 µg/mL)

The row we do not tick

Teriparatide sits in the table with no green mark, because 0.08 mL has no direct equivalent in our released range. We could have left the row out. Listing it is more useful to you: if your program is a short-travel, high-resolution dose, that is a tooling conversation to have at the first call rather than a discovery at validation.

The same honesty applies in the other direction. "Covered" here means the travel range can reach your dose volume. It does not mean the platform is qualified for your product — that requires feasibility samples, dose accuracy testing to ISO 11608-1 and a joint validation plan.

What this page is not

This is a device capability comparison, not a therapeutic claim. Nothing here states that a webosan pen is indicated for, or approved with, any medicine. Dose regimens are governed by the approved labelling in your market, and the device decision follows from your fill volume, concentration and target increment — confirmed per program.

Questions buyers ask about dose range

What is the minimum deliverable dose of your injection pens?
The minimum increment is 0.01 mL on standard ranges, or 0.0208 mL on the variant we use for 0.75 mL travel. Whether the smallest deliverable dose meets your target depends on your concentration, so we confirm it against your fill volume rather than quoting a single figure.
Can one pen mechanism cover a full titration schedule?
Sometimes. If every strength sits in the same container volume, one mechanism covers the schedule and only the scale print changes. If the schedule moves between container volumes, as semaglutide does between 0.50 and 0.75 mL, the travel range must cover the larger one and the marking carries the difference.
Do you supply a list of compatible drugs?
No. A list of drug names with ticks beside it cannot be verified by the buyer and dates quickly. We publish travel ranges, increments and container formats, and compare them to publicly documented dose volumes so your team can check the fit itself.

Dose coverage

Have a fill volume and a target increment?

Send the concentration, the dose ladder and the increment you need. We will reply with the travel range that fits, the scale marking that follows from it, and whether it needs existing tooling or a variant.

Continue on WhatsApp

Include concentration, dose ladder and increment - that is enough for a travel-range answer.